MADRID—Systemic lupus erythematosus (SLE) experts in North America and Europe are working together to refine the classification system for the disease, with the goal of producing a new set of criteria that is simpler to use and more scientifically rigorous than any classification approach previously published, speakers involved with the process said at the 2017…
Comorbidities & Risk Factors for Developing SLE
MADRID—Researchers have found that systemic lupus erythematosus (SLE) is independently linked with bipolar disorder and say the findings point to a need for greater awareness of psychiatric problems in patients with SLE. In work led by investigators at Tel Aviv University in Israel and presented at the 2017 Annual European Congress on Rheumatology (EULAR), researchers…
Rituximab May Help Pediatric Patients with SLE
Although rituximab is not indicated for adults with SLE, a recent review suggests that it may be safe and effective for treating pediatric SLE. The review found that rituximab improved renal function and reduced proteinuria in pediatric patients. It may also prevent relapse and improve disease activity…
Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease
New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…
BAFF: A Fulcrum Between Resistance to Infection & Autoimmunity
New research has linked a TNFSF13B variant and B cell activating factor (BAFF), a common therapeutic target, with multiple sclerosis and systemic lupus erythematosus. The variant is a disease-risk allele associated with increased levels of soluble BAFF…
The Biomarkers of Lupus Disease Study
Most SLE clinical trials continue standard background medications being taken by patients at entry, based on assumptions that this minimizes the risk of serious flares and that immunologic interference is minimal. These assumptions are not evidence based, but eliminating polypharmacy in trials studying patients with active lupus remains controversial. These researchers tested the withdrawal of immunosuppressants to make SLE trial results more interpretable…
One Stop: Multi-Disciplinary Lupus Clinic Meets Patient Needs
Multi-disciplinary care may be a slowly growing trend. One clinic in Ohio is raising the bar for lupus patients, serving as a one-stop center for diagnostic testing, imaging services and physical therapy. The clinic is also able to conduct basic research to advance lupus treatment and tests…
Dermatology Consults May Cut Hospital Stays, Readmissions
NEW YORK (Reuters Health)—Inpatient dermatology consultations were associated with shorter hospital stays and reduced readmissions in a U.S. medical center and may do the same elsewhere, researchers in Ohio suggest. “A few decades ago, patients with severe psoriasis, drug reactions, blistering diseases and even severe eczema would be admitted to the hospital under close dermatology…
Liquid Biopsy Provides Insights into Lupus
Microparticles in the blood of SLE patients may be a source of extracellular HMGB1, which is involved in immune response. Researchers found that analysis may be able to determine if the patient is producing dead, dying and activated cells that are important for SLE pathogenesis…
Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
Advancing the understanding of autoimmune diseases has implications for precision medicine, according to Robert Carter, MD, of the NIH. Research funded through the NIH’s Accelerating Medicines Partnership has the potential to develop better biomarkers and clinical trials for lupus and RA, paving the way for more personalized treatment…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »